|
Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms
Seug Yun Yoon, Sung-Yong Kim
Korean J Intern Med. 2023;38(6):810-817. Published online November 1, 2023
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells. The malignant clones produce cytokines that drive self-perpetuating inflammatory responses and tend to transform into more aggressive clones, leading to disease progression. The progression of MPNs follows a biolog..
|
|
|
Infectious diseases
Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant
Taeeun Kim, Hyun-Jeong Lee, Sun-Mi Kim, Joo Hee Jung, Sung Shin, Young-Hoon Kim, Heungsup Sung, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Sung-Han Kim, Duck Jong Han
Korean J Intern Med. 2020;35(2):438-448. Published online June 7, 2018
Background/Aims: We evaluated the usefulness in kidney transplant (KT) candidates of cytomegalovirus (CMV)-specific enzyme-linked immunospot (ELISPOT) assays for predicting the development of post-transplant CMV infections.
Methods: All adult recipients admitted for living-donor KT between March 20..
|
|
|
Pulmonology
QuantiFERON-TB Gold PLUS versus QuantiFERON- TB Gold In-Tube test for diagnosing tuberculosis infection
Soo Han Kim, Kyung-Wook Jo, Tae Sun Shim
Korean J Intern Med. 2020;35(2):383-391. Published online December 26, 2019
Background/Aims: QuantiFERON-TB Gold PLUS (QFT-PLUS) was developed as a new version of the interferon-γ (IFN-γ) release assay that contains an extra antigen tube to elicit a CD8+ T-cell response in addition to a CD4+ T-cell response. This study aimed to evaluate the performances of QFT-PLUS versus..
|
|
|
Rheumatology
Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases
Junhee Pyo, Soo-Kyung Cho, Dam Kim, Yoon-Kyoung Sung
Korean J Intern Med. 2018;33(6):1241-1251. Published online December 28, 2017
Background/Aims: To estimate the level of agreement and positivity rates of latent tuberculosis infection (LTBI) tests prior to the use of tumor necrosis factor (TNF) inhibitors in relation to underlying rheumatic diseases and endemic tuberculosis levels.
Methods: The Ovid-Medline, Embase, and Coch..
|
|
|
Development of bronchiolitis obliterans organizing pneumonia during standard treatment of
hepatitis C with Peg-IFNα2b
Eun Chung, Kihoon Park, Jo Heon Kim, Nam Ik Han, Young Sok Lee, Si Hyun Bae, Chung-Hwa Park
Korean J Intern Med. 2017;32(6):1098-1100. Published online August 21, 2017
|
|
|
Gastroenterology
Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection
In Soo Oh, Joung Won Won, Hyung Joon Kim, Hyun Woong Lee
Korean J Intern Med. 2017;32(6):1010-1017. Published online August 11, 2017
Background/Aims: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the..
|
|
|
Pulmonology
Comparing tuberculin skin test and interferon γ release assay (T-SPOT.TB) to diagnose latent tuberculosis infection in household contacts
Hyun Woo Lee, Yeon Joo Lee, Se Joong Kim, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Choon-Taek Lee, Jae-Ho Lee
Korean J Intern Med. 2017;32(3):486-496. Published online January 24, 2017
Background/Aims: The tuberculin skin test (TST) and interferon γ release assay are currently used as diagnostic tools to detect latent tuberculosis (TB) infection; however, there are inconsistencies about the degree of agreement between the tests. We aimed to evaluate the concordance rate between ..
|
|
|
Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
I-Nae Park, Tae Sun Shim
Korean J Intern Med. 2017;32(2):302-308. Published online December 13, 2016
Background/Aims: The usefulness of interferon-γ release assays (IGRAs) in monitoring to responses to anti-tuberculosis (TB) treatment is controversial. We compared the results of two IGRAs before and after anti-TB treatment in same patients with active TB.
Methods: From a retrospective review, we..
|
|
|
Gastroenterology
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
Yong Hwang, Won Kim, So Young Kwon, Hyung Min Yu, Jeong Han Kim, Won Hyeok Choe
Korean J Intern Med. 2015;30(6):792-800. Published online October 30, 2015
Background/Aims: Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was to investigate the incidence, outcomes, and risk factors for TD during pegylated interferon (PEG-..
|
|
|
Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
Tae-Hee Lee, Kee-Ook Lee, Yong-Seok Kim, Sun-Moon Kim, Kyu-Chan Huh, Young-Woo Choi, Young-Woo Kang
Korean J Intern Med. 2014;29(3):370-374. Published online April 29, 2014
Various adverse events have been reported during combination therapy with pegylated (PEG)-interferon-α and ribavirin, although opportunistic infections, especially cryptococcal meningitis, are very rare. A 61-year-old woman complained of headaches and a fever during treatment of a chronic hepatiti..
|
|
|
Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kwan Soo Byun, Seung Woon Paik, Young Suk Lim, Han Chu Lee, Kwang Hyub Han, Kwan Sik Lee
Korean J Intern Med. 2009;24(3):203-211. Published online August 26, 2009
Background/AimsThe virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect o..
|
|
|
